A Phase 2 interventional study of SAR445088 (BIVV020) in Immune Thrombocytopenia (ITP), sponsored by Bioverativ, a Sanofi company. Completed at 9 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-10.
Sponsored by Bioverativ, a Sanofi company (part of Sanofi) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Spain — 14 open to participants now, 18 under way, 9 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Spain.
Among the 50 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Spain, this one is the 43rd largest by enrollment of the 44 interventional ones that give a count, is one of 3 that started in 2021, is one of 11 in phase 2, and was the 25th registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →14 of the 50 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Spain are open now. Recruiting first, the newest first:
TargED Biopharmaceuticals B.V. · Sites in Spain
Ages 18+
CRISPR Therapeutics AG · Sites in Spain, United States, Germany
Ages 18+
Incyte Corporation · Sites in Spain, United States, Australia and 4 more countries
Ages 18+
Sanofi · Sites in Spain, United States, Austria and 7 more countries
Ages 18+
argenx · Sites in Spain, France, Germany and 7 more countries
Ages 12–17
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 18 · Phase 3 23
First in 2006; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 69 across the 44 interventional studies, 131 across the 6 observational. Of the 31 that completed or were terminated, 21 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 50 have an industry lead sponsor. The 10 most frequent:
This study is registered under Bioverativ, a Sanofi company, one of the names counted as Sanofi. Under that name alone:
Bioverativ, a Sanofi company is the lead sponsor of 16 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 7 (58%) have results posted.
Sanofi has 8 studies filed under Purpura, Thrombocytopenic, Idiopathic — fewer than ten, so there is no comparison to draw.
5 of the studies in Purpura, Thrombocytopenic, Idiopathic with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07059000Phase 3Kedrion S.p.A.A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP) | 2026-12 |
| NCT07007962Phase 3SanofiStudy to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment | 2027-11-05 |
| NCT06371417Chugai PharmaceuticalPhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) | 2027-03-31 |
| NCT07043946Climb Bio, Inc.A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP) | 2027-08 |
| NCT07104565Incyte CorporationStudy to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders | 2027-09-23 |
Add all 5 to your calendar (.ics) → With an account.
Among the 50 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
- To evaluate the effect of BIVV020 on the durability of platelet response in participants with persistent/chronic immune thrombocytopenia (ITP)
Secondary Objectives:
Study duration:
Visit frequency:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For participants who have not previously received sutimlimab: persistent/chronic ITP (ITP lasting for ≥6 months) and all the following conditions:
Exclusion criteria:
Participants were excluded from the study if any of the following criteria apply:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received SAR445088 (BIVV020).
Drug: SAR445088 (BIVV020)
Pharmaceutical form:solution for injection
Percentage of Participants With a Durable Platelet Response
A naive participant was a participant who did not use sutimlimab prior to enrollment. A switcher was a participant who used sutimlimab prior to enrollment. A naive participant was a responder if the platelet count was \>=50 × 10\^9/liter (L) at \>=50 percent (%) of scheduled visits, or for participants with baseline platelet count \<15 × 10\^9/L, a \>=20 × 10\^9/L increase in platelet count from baseline at \>=50% of scheduled visits, without receiving rescue immune thrombocytopenia (ITP) therapy. A switcher was a responder if the maintenance platelet count was \>=30 × 10\^9/L at \>=50% of scheduled visits, without receiving rescue ITP therapy.
Time frame: From Week 3 to Week 24
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious AEs (SAE)
An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. SAEs were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were AEs that developed after the first study treatment administration in the safety analysis period which was defined as the period from the first study intervention administration to the end of study (EOS) visit (up to Week 103).
Time frame: From first study treatment administration (Day 1) up to Week 103
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematology
Criteria for potentially clinically significant laboratory abnormalities (PCSA): White blood cells: less than (\<)3.0 Giga/L (Non-Black \[NB\]) or \<2.0 Giga/L (Black \[B\]), greater than or equal to (\>=)16.0 Giga/L; Lymphocytes: greater than (\>)4.0 Giga/L; Neutrophils: \<1.5 Giga/L (NB) or \<1.0 Giga/L (B); Monocytes: \>0.7 Giga/L; Basophils: \>0.1 Giga/L; Eosinophils: \>0.5 Giga/L or \>upper limit of normal (ULN) (if ULN \>=0.5 Giga/L); Hemoglobin: less than or equal to (\<=) 115 grams per liter (g/L) (Male\[M\]) or \<=95 g/L (Female\[F\]), \>=185 g/L (M) or \>=165 g/L (F), Decrease from baseline (DFB) \>=20 g/L; Hematocrit: \<=0.37 volume/volume (v/v) (M) or \<=0.32 v/v (F); Red blood cells (RBC): \>=6 Tera/L; Platelets:\<100 Giga/L, \>=700 Giga/L. Only the worst case during the treatment-emergent (TE) period for each participant with worsening from baseline is presented.
Time frame: On Days 1, 15, 29, at Weeks 8, 12, 24, and then every 8 weeks until the end of study (EOS) (Week 103)
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Clinical Chemistry
Criteria for PCSA: Blood Urea Nitrogen: \>=17 millimole (mmol)/L; Creatinine: \>=150 micromole (mcmol)/L (Adults), \>=30% and \<100% change from baseline, \>=100% change from baseline; Potassium: \<3 mmol/L, \>=5.5 mmol/L; Sodium: \<=129 mmol/L, \>=160 mmol/L; Aspartate Aminotransferase (AST): \>3 ULN, \>5 ULN, \>10 ULN, \>20 ULN; Alanine Aminotransferase (ALT): \>3 ULN, \>5 ULN, \>10 ULN, \>20 ULN; Alkaline Phosphatase (ALP): \>1.5 ULN; Bilirubin: \>1.5 ULN, \>2 ULN; ALT and Total Bilirubin: ALT \>3 ULN and TBILI \>2 ULN. Only the worst case during the TE period for each participant with worsening from baseline is presented.
Time frame: On Days 1, 15, 29, Weeks 8, 12 and 24, then every 8 weeks until the EOS (Week 103)
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Coagulation
The number of participants with PCSA for coagulation parameters during the TE period without PCSA definition by biological function are presented. The parameters evaluated were prothrombin time, prothrombin international normalized ratio and activated partial thromboplastin time (APTT).
Time frame: On Days 1, 15, 29, Weeks 8, 12 and 24, then every 8 weeks until the EOS (Week 103)
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Urinalysis
Criteria for PCSA: potential of Hydrogen (pH) \<=4.6, \>=8. Only the worst case during the TE period for each participant with worsening from baseline is presented.
Time frame: On Days 1, 15, 29, Weeks 8, 12 and 24, then every 8 weeks until the EOS (Week 103)
Plasma Concentrations of SAR445088 (BIVV020)
Plasma samples were collected at specified timepoints.
Time frame: 1-hour post-dose on Day 1, on Days 8, 15, 29, 43, at Weeks 12, 16, 24, 32, 40, 48, 56, 64, 72, 80 and EOS visit, up to 103 weeks
Number of Responders to SAR445088 (BIVV020)
A participant was a responder if the platelet count was \>=50 × 10\^9/L and there was a greater than 2-fold increase from baseline, measured on 2 occasions at least 7 days apart with the absence of bleeding \[bleeding score \>=2 on the World Health Organization (WHO) bleeding scale\] while the platelet counts were maintained above the threshold and lack of combination ITP therapy during this period. WHO bleeding scores: 1=Petechiae; 2=Mild blood loss; 3=Gross blood loss; and 4=Debilitating blood loss.
Time frame: At Weeks 24 and 56
Time to First Platelet Response
Time to first platelet response was defined as greater than or equal to each of the following values: 50 × 10\^9/L or 100 × 10\^9/L (confirmed by 2 measurements at least 7 days apart). It was calculated as date of first occurrence of confirmed platelet count response before rescue therapy.
Time frame: From Baseline (Day 1) up to Week 56
Percentage of Participants Who Did Not Require Rescue Therapy for an Acute Episode of Thrombocytopenia After Week 3
Data was collected to assess the effect of treatment with SAR445088 (BIVV020) on the requirement for rescue ITP therapy.
Time frame: Up to Week 84
Number of Participants With Anti-Drug Antibody (ADAs) Response to SAR445088 (BIVV020)
Plasma samples were analyzed for the presence of ADAs for SAR445088 (BIVV020) using validated assays. Treatment-induced ADA was defined as ADAs that developed during the treatment-emergent period and without pre-existing ADA. Pre-existing ADA was defined as ADAs present in samples drawn before first study treatment administration. Treatment-boosted ADA positive was defined as pre-existing ADA (i.e., ADA positive at baseline) that was boosted at least a 9-fold increase of titer values during the treatment-emergent period than the baseline. Treatment-emergent ADA positive was defined as either treatment-induced ADA positive or treatment-boosted ADA positive during the treatment-emergent period. Inconclusive ADA was defined as the one that could not irrefutably be classified as with or without treatment-emergent ADA.
Time frame: Up to Week 103
The study was conducted at 8 centers in 5 countries. A total of 20 participants were screened from 04 Feb 2021 to 07 Sep 2021, of which 8 were screen failures due to not meeting eligibility criteria.
| Milestone | SAR445088 |
|---|---|
| Started | 12 |
| Completed | 5 |
| Not completed | 7 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Other | 6 |
A naive participant was a participant who did not use sutimlimab prior to enrollment. A switcher was a participant who used sutimlimab prior to enrollment. A naive participant was a responder if the platelet count was \>=50 × 10\^9/liter (L) at \>=50 percent (%) of scheduled visits, or for participants with baseline platelet count \<15 × 10\^9/L, a \>=20 × 10\^9/L increase in platelet count from baseline at \>=50% of scheduled visits, without receiving rescue immune thrombocytopenia (ITP) therapy. A switcher was a responder if the maintenance platelet count was \>=30 × 10\^9/L at \>=50% of scheduled visits, without receiving rescue ITP therapy.
| percentage of participants | SAR445088 |
|---|---|
| Naive participant | 0 (0.0 to 36.9) |
| Switcher | 25 (19.4 to 99.4) |
An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. SAEs were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were AEs that developed after the first study treatment administration in the safety analysis period which was defined as the period from the first study intervention administration to the end of study (EOS) visit (up to Week 103).
| Participants | SAR445088 |
|---|---|
| Any TEAE | 8 |
| Any Treatment Emergent SAE | 2 |
Criteria for potentially clinically significant laboratory abnormalities (PCSA): White blood cells: less than (\<)3.0 Giga/L (Non-Black \[NB\]) or \<2.0 Giga/L (Black \[B\]), greater than or equal to (\>=)16.0 Giga/L; Lymphocytes: greater than (\>)4.0 Giga/L; Neutrophils: \<1.5 Giga/L (NB) or \<1.0 Giga/L (B); Monocytes: \>0.7 Giga/L; Basophils: \>0.1 Giga/L; Eosinophils: \>0.5 Giga/L or \>upper limit of normal (ULN) (if ULN \>=0.5 Giga/L); Hemoglobin: less than or equal to (\<=) 115 grams per liter (g/L) (Male\[M\]) or \<=95 g/L (Female\[F\]), \>=185 g/L (M) or \>=165 g/L (F), Decrease from baseline (DFB) \>=20 g/L; Hematocrit: \<=0.37 volume/volume (v/v) (M) or \<=0.32 v/v (F); Red blood cells (RBC): \>=6 Tera/L; Platelets:\<100 Giga/L, \>=700 Giga/L. Only the worst case during the treatment-emergent (TE) period for each participant with worsening from baseline is presented.
| Participants | SAR445088 |
|---|---|
| White blood cells: <3.0 Giga/L (NB) or <2.0 Giga/L (B) | 0 |
| White blood cells: >=16.0 Giga/L | 3 |
| Lymphocytes: >4.0 Giga/L | 2 |
| Neutrophils: <1.5 Giga/L (NB) or <1.0 Giga/L (B) | 0 |
| Monocytes: >0.7 Giga/L | 7 |
| Basophils: >0.1 Giga/L | 3 |
| Eosinophils: >0.5 Giga/L or >ULN (if ULN >=0.5 Giga/L) | 1 |
| Hemoglobin: <=115 g/L (M) or <=95 g/L (F) | 0 |
| Hemoglobin: >=185 g/L (M) or >=165 g/L (F) | 0 |
| Hemoglobin: DFB >=20 g/L | 0 |
| Hematocrit: <=0.37 v/v (M) or <=0.32 v/v (F) | 0 |
| RBC: >=6 Tera/L | 0 |
| Platelets: <100 Giga/L | 11 |
| Platelets: >=700 Giga/L | 0 |
Criteria for PCSA: Blood Urea Nitrogen: \>=17 millimole (mmol)/L; Creatinine: \>=150 micromole (mcmol)/L (Adults), \>=30% and \<100% change from baseline, \>=100% change from baseline; Potassium: \<3 mmol/L, \>=5.5 mmol/L; Sodium: \<=129 mmol/L, \>=160 mmol/L; Aspartate Aminotransferase (AST): \>3 ULN, \>5 ULN, \>10 ULN, \>20 ULN; Alanine Aminotransferase (ALT): \>3 ULN, \>5 ULN, \>10 ULN, \>20 ULN; Alkaline Phosphatase (ALP): \>1.5 ULN; Bilirubin: \>1.5 ULN, \>2 ULN; ALT and Total Bilirubin: ALT \>3 ULN and TBILI \>2 ULN. Only the worst case during the TE period for each participant with worsening from baseline is presented.
| Participants | SAR445088 |
|---|---|
| Blood Urea Nitrogen: >=17 mmol/L | 0 |
| Creatinine: >=150 mcmol/L (Adults) | 1 |
| Creatinine: >=30% and < 100% from baseline | 4 |
| Creatinine:>=100% from baseline | 1 |
| Potassium: <3 mmol/L | 0 |
| Potassium: >=5.5 mmol/L | 1 |
| Sodium:<=129 mmol/L | 0 |
| Sodium: >=160 mmol/L | 0 |
| AST: >3 ULN | 0 |
| AST: >5 ULN | 0 |
| AST: >10 ULN | 0 |
| AST: >20 ULN | 0 |
| ALT: >3 ULN | 0 |
| ALT: >5 ULN | 0 |
| ALT: >10 ULN | 0 |
| ALT: >20 ULN | 0 |
| ALP: > 1.5 ULN | 1 |
| Bilirubin: >1.5 ULN | 0 |
| Bilirubin: >2 ULN | 0 |
| ALT and total bilirubin: ALT>3ULN and TBILI >2ULN | 0 |
The number of participants with PCSA for coagulation parameters during the TE period without PCSA definition by biological function are presented. The parameters evaluated were prothrombin time, prothrombin international normalized ratio and activated partial thromboplastin time (APTT).
| Participants | SAR445088 |
|---|---|
| Prothrombin time: <Lower limit of normal (LLN) | 1 |
| Prothrombin time: >ULN | 2 |
| Prothrombin International Normalized Ratio: <LLN | 2 |
| Prothrombin International Normalized Ratio: >ULN | 2 |
| APTT: <LLN | 1 |
| APTT: >ULN | 3 |
Criteria for PCSA: potential of Hydrogen (pH) \<=4.6, \>=8. Only the worst case during the TE period for each participant with worsening from baseline is presented.
| Participants | SAR445088 |
|---|---|
| pH: <=4.6 | 0 |
| pH: >=8 | 1 |
Plasma samples were collected at specified timepoints.
| microgram/milliliter (mcg/mL) | SAR445088 |
|---|---|
| Day 1: 1-hour post-dose | 1186.00 ± 254.24 |
| Day 8 | 668.09 ± 139.19 |
| Day 15 | 657.64 ± 107.33 |
| Day 29 | 631.80 ± 64.52 |
| Day 43 | 627.56 ± 84.39 |
| Week 12 | 736.78 ± 164.07 |
| Week 16 | 786.00 ± NA |
| Week 24 | 781.63 ± 276.73 |
| Week 32 | 695.67 ± 343.75 |
| Week 40 | 602.33 ± 385.64 |
| Week 48 | 559.33 ± 300.73 |
| Week 56 | 602.80 ± 224.08 |
| Week 64 | 615.80 ± 247.91 |
| Week 72 | 584.25 ± 243.37 |
| Week 80 | 602.50 ± 287.79 |
| EOS (Week 103) | 206.46 ± 157.42 |
A participant was a responder if the platelet count was \>=50 × 10\^9/L and there was a greater than 2-fold increase from baseline, measured on 2 occasions at least 7 days apart with the absence of bleeding \[bleeding score \>=2 on the World Health Organization (WHO) bleeding scale\] while the platelet counts were maintained above the threshold and lack of combination ITP therapy during this period. WHO bleeding scores: 1=Petechiae; 2=Mild blood loss; 3=Gross blood loss; and 4=Debilitating blood loss.
| Participants | SAR445088 |
|---|---|
| Week 24 | 2 |
| Week 56 | 2 |
Time to first platelet response was defined as greater than or equal to each of the following values: 50 × 10\^9/L or 100 × 10\^9/L (confirmed by 2 measurements at least 7 days apart). It was calculated as date of first occurrence of confirmed platelet count response before rescue therapy.
| weeks | SAR445088 |
|---|---|
| Platelet count>=50 x 10^9/L | 18.5 (13.5 to 49.5) |
| Platelet count>=100 x 10^9/L | 18.5 (13.5 to 49.5) |
Data was collected to assess the effect of treatment with SAR445088 (BIVV020) on the requirement for rescue ITP therapy.
| percentage of participants | SAR445088 |
|---|---|
| Week 3 to Week 24 during treatment period | 75.0 |
| Week 3 to Week 56 during treatment period | 75.0 |
| Week 3 to the end of on-treatment period | 75.0 |
Plasma samples were analyzed for the presence of ADAs for SAR445088 (BIVV020) using validated assays. Treatment-induced ADA was defined as ADAs that developed during the treatment-emergent period and without pre-existing ADA. Pre-existing ADA was defined as ADAs present in samples drawn before first study treatment administration. Treatment-boosted ADA positive was defined as pre-existing ADA (i.e., ADA positive at baseline) that was boosted at least a 9-fold increase of titer values during the treatment-emergent period than the baseline. Treatment-emergent ADA positive was defined as either treatment-induced ADA positive or treatment-boosted ADA positive during the treatment-emergent period. Inconclusive ADA was defined as the one that could not irrefutably be classified as with or without treatment-emergent ADA.
| Participants | SAR445088 |
|---|---|
| Participants with ADA negative or missing at baseline | 11 |
| Participants with treatment-induced ADA | 0 |
| Participants with pre-existing ADA | 1 |
| Participants with treatment-boosted ADA | 0 |
| Participants with treatment-emergent ADA during 24-week treatment period | 0 |
| Participants with treatment-emergent ADA during 52-week treatment period | 0 |
| Participants without treatment-emergent ADA | 12 |
| Participants with inconclusive ADA | 0 |
Collected over The TEAEs were collected from first study treatment administration (Day 1) up to Week 103. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SAR445088 | 0/12 (0%) | 2/12 (16.7%) | 8/12 (66.7%) |
| Event | SAR445088 |
|---|---|
| AppendicitisInfections and infestations | 1/12 |
| Cerebrovascular AccidentNervous system disorders | 1/12 |
| Abdominal Pain UpperGastrointestinal disorders | 1/12 |
| Event | SAR445088 |
|---|---|
| Covid-19Infections and infestations | 3/12 |
| FatigueGeneral disorders | 3/12 |
| DiarrhoeaGastrointestinal disorders | 2/12 |
| InfluenzaInfections and infestations | 1/12 |
| Post-Acute Covid-19 SyndromeInfections and infestations | 1/12 |
| SinusitisInfections and infestations | 1/12 |
| LymphadenopathyBlood and lymphatic system disorders | 1/12 |
| Decreased AppetiteMetabolism and nutrition disorders | 1/12 |
| HyperglycaemiaMetabolism and nutrition disorders | 1/12 |
| AphasiaNervous system disorders | 1/12 |
Enrolled population consisted of all participants from screened population who had been allocated to a treatment regardless of whether the treatment was received or not.
| Age, Continuous(years) | SAR445088 |
|---|---|
| Mean | 54.7 ± 10.1 |
| Sex: Female, Male(Participants) | SAR445088 |
|---|---|
| Female | 4 |
| Male | 8 |
| Race (NIH/OMB)(Participants) | SAR445088 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 7 |
| More than one race | 0 |
| Unknown or Not Reported | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Feb 2021 to primary completion in Feb 2022, 12 months.
Results were first posted in Feb 2024, 2 years after primary completion. A results delay was requested in Feb 2023.
Of 66 phase 2 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Riliprubart
Purpura, Thrombocytopenic, Idiopathic →
Bioverativ, a Sanofi company →